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WAKING UP TO SLEEPINESS: MODAFINIL, THE MEDIA AND 











Recent years have witnessed an upsurge of sociological interest in 
pharmaceuticals, including on-going research on the regulation of the 
pharmaceutical industry (Abraham 1995, Abraham and Lewis 2002); 
related debates on globalisation and the pharmaceutical industry (Busfield 
2003); the role of the pharmaceutical industry in ‘disease mongering’ 
(Blech 2006) and the medicalisation of society (Conrad 2007); the 
meaning and use of medications in lay culture and everyday life (Britten 
1996, Gabe and Lipshitz-Phillips 1982), and; studies of pharmacies, 
pharmacists, prescribing and concordance (Britten et al 2004, Stevenson 
et al 2002, Harding and Taylor 1997). 
 
(i) Pharmaceuticals and the media 
 
Another key issue here concerns the role and function of the media in 
relation pharmaceuticals and the pharmaceuticalisation of everyday life. 
Media coverage of pharmaceuticals, as previous studies have shown, is 
complex and variable over time. Often, when drugs are first discovered or 
licensed, media coverage tends to be positive in tone and content, 
including enthusiastic headlines extolling the virtues of a new 
‘breakthrough’ or ‘wonder drug’. Nelkin (1995), for example, highlights 
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the wave of enthusiastic media attention which Prozac (dubbed the ‘feel 
good drug’) received in the 1990s, with Viagra subsequently following in 
its footsteps. If or when unwelcome side effects become apparent, 
however, or misuse of some sort on the part of doctors or the lay 
populace is detected, then negative constructions or demonisation of the 
drug in question seems to predominate or prevail. We see this very 
clearly, for example, with regard to media coverage of benzodiazepines 
over time. Gabe and Bury (1996), for instance, note the considerable 
media attention devoted to the risks of taking benzodiazepines over the 
last 40 years. When first prescribed to patients in the 1960s, the media 
gave these drugs a ‘generally enthusiastic welcome’ (1996: 76). As this 
new generation of tranquillizers became more popular, however, their 
therapeutic value ceased to be ‘newsworthy’, with more critical coverage 
developing from the 1970s onwards -- coverage highlighting both the 
risks of the drugs ‘addictive potential’ and journalistic imperatives for 
‘dramatisation’ and ‘personalisation’ (1996: 78. See also Cohen 1983).  
 
Media treatment of medicines and drugs then, as Seale comments, 
‘demonstrates a tendency to idealise or stigmatise, creating oppositional 
extremes’ (2002: 152: See also Entwistle and Sheldon 1999). Rarely do 
the media present a ‘balanced picture of harm and benefit contained in a 
single substance’ (2002: 148). Whilst the actions of drug companies, 
indeed, are often subject to criticism, the media are frequently accused of 
promoting rather than challenging pharmaceutical interests, wittingly or 
unwittingly: a point which returns us notions of ‘disease mongering’ 
mentioned above (see, for example, Blech 2006 and Moynihan et al. 
2002). Whilst ‘new’ media such the Internet, moreover, may provide 
spaces or forums to challenge or resist these processes, they may equally 
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provide new avenues or channels for the medicalisation or 
pharmaceuticalisation of daily life (see, for example, Fox et al. 2005). 
 
(ii) Modafinil: The shape of things to come? 
 
It is against this backdrop of recent sociological work on pharmaceuticals 
in general and the role of the media in relation to pharmaceuticals in 
particular, that this paper is located. Our focus, in contrast to the previous 
studies, is on British newspaper coverage of the new wakefulness-
promoting drug Modafinil, a drug manufactured by the American 
Pennsylvania-based pharmaceutical company Cephalon, under the brand 
name Provigil 1. Originally approved for the treatment of excessive 
daytime sleepiness associated with narcolepsy, Provigil has now received 
both Federal Drugs Administration (FDA) and Medicines and Healthcare 
products Regulatory Agency (MHRA) approval for the treatment of 
excessive sleepiness associated with obstructive sleep apnoea. 
Additionally, it has now received FDA approval for the treatment of 
excessive sleepiness associated with ‘shift work sleep disorder’ 
(www.Cephalon.com; www.provigil.com).  Provigil, it is claimed, is a 
drug that truly breaks new ground. Unlike former stimulants, Modafinil 
(an ampekine) is a eugeroic drug (Greek for ‘good arousal) that can 
promote alert wakefulness with none of the buzz, jitteriness or highs and 
lows of its predecessors. It has also been found to improve memory, 
cognition performance , mood and concentration and is, supposedly, non-
addictive with few reported side-effects. Perhaps most remarkably of all, 
Modafinil does not disturb sleep and only seems to promote wakefulness 
‘under conditions where vigilance is sought by the person who has taken 
it’ (Wolpe 2002: 391).  
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The market potential of this drug is huge, as Cephalon’s year-on-year 
sales figures clearly attest (http://www.Cephalon.com). Cephalon, indeed, 
appear to be a very enterprising company having joined the list of 
companies included in the Fortune 1000 annual rankings of America’s 
largest corporations (http://www.cephalon.com). A recent feature on 
Cephalon in BusinessWeek, moreover -- tellingly entitled ‘Eyes wide 
open’ and proudly posted on Cephalon’s own website -- suggests that the 
Company business strategy can serve as a model or exemplar for other 
biopharmaceutical enterprises. ‘Cephalon’s scientists’, the article 
proclaims, ‘respond to doctors who report that Provigil is helpful with 
various disorders such as sleep apnoea. Collaborating with doctors, 
Cephalon can provide the FDA with persuasive data on these ailments, 
and thus expand the use of the drug’ (http//:www.Cephalon.com).  
 
The potential market for Modafinil, however, extends far beyond the 
boundaries or confines of the doctor’s surgery or sleep clinic, including a 
significant ‘off-label’ market. As with a range of other so-called 
‘enhancement’ technologies designed to make us ‘better than well’ or 
‘better humans’ (Miller and Wilsdon 2006; Parens 1998), if not ‘better 
than human’, Modafinil therefore raise some intriguing if not disturbing 
social and ethical questions, which in this particular case translate into 
debates over the prospects and possibilities of a world in which 
wakefulness, for better or worse, can be more or less readily conjured at 
will or manufactured/medicated on demand. 
 
What then do the media make of Modafinil? How is Modafinil being 
constructed and represented in the British press? What cultural 
commonsenses are being circulated and conveyed regarding this new 
drug? Are there any particular points of convergence or consensus, 
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contestation or controversy in this newspaper coverage? And what does 
this tell us about the role of the media in the medicalisation or 
pharmaceuticalisation of alertness and the governance of sleepy bodies in 
contemporary culture? These are some the questions this article seeks to 







Methodological matters: Retrieving and analysing newspaper stories 
 
This paper is part of a broader project on social constructions of sleep in 
the British print news media. The study, in this respect, was primarily 
concerned with print media discourses and debates on sleep, rather than 
audience reception of and responses to these messages, or the institutional 
arrangements involved in the production of news. 
Articles for the study were retrieved from the Lexis Nexis archival 
database. Our selection of 6 UK national newspaper texts (Times, 
Guardian, Independent, Daily Mail, Daily Mirror, Sun and their Sunday 
equivalents) was influenced by knowledge of the circulation figures and 
readership profiles (obtained from circulation figures on the Newspaper 
Marketing Agency website www.nmauk.co.uk), alongside sampling for 
contrasting tone, format and political orientation.  
 
All searches started from the date of first loading onto the Lexis Nexis 
database until 31st August 2006 2, using search terms such as ‘Modafinil’, 
‘Provigil’, ‘wakefulness promoting drugs’. As it was substantial press 
coverage we were most interested in, for the purposes of this particular 
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paper at least, articles were selected from inclusion in the study if any of 
these search terms were mentioned three or more times. This resulted in a 
total of 54 articles across all papers sampled, with a higher proportion of 
articles in the more ‘serious papers’ – a finding which held across all 
search criteria deployed.   
 
A variety of different techniques are now available for the analysis of 
media materials in general and newspapers in particular, including more 
quantitative forms of analysis such as content analysis and more 
qualitative forms of analysis such as discourse analysis (Fenton et al. 
1998, Potter 1996). Our own approach favoured a more qualitative 
approach. Articles were read, catalogued and compared in terms of key 
words and phrases, key developing issues and storylines, the use of 
'experts' and/or research data, evidence of medicalisation/disease 
mongering, how the reader was addressed/drawn into the piece, and the 
vocabulary used, particularly the 'moral' messages, rhetorical styles 
and/or 'emotional' overtones of these selected articles. Emerging debates 
and discourses were then used as an aid to further qualitative, interpretive 
analysis on how such articles constructed their subject matter and how 
they were intended to be read.  
 
Discourses and Debates: Medicalisation and beyond 
 
Four main themes emerged in our sample, which pertain respectively to 
the following uses and abuses of Modafinil/Provigil: (i) clinical treatment 
of medical conditions; (ii) lifestyle choices; (iii) military operations; (iv) 
(un)fair competition. The distribution of these four themes according to 












As Table 1 indicates, the most commonly reported theme in our sample 
as a whole pertained to (un)fair competition, primarily in the field of 
sport, followed by medical matters, lifestyle choices and finally military 
uses and abuses of the drug. The Times was the paper in which the 
clinical and medical applications of Modafinil featured most often, 
followed by the Mail and the Independent. Concerns over the drug as a 
lifestyle choice were also most evident in the Times, followed by the 
Independent and the Mail. Military coverage, in contrast, was almost 
exclusively featured in the Guardian, centred on an issue which 
materialised in 2004 – see Table 2. Similarly, the majority of press 
coverage of sporting competition across all newspapers pertained to an 
event that materialised in 2003 and rumbled on into 2004 – see Table 2. 
 
As Table 2 indicates, apart from a couple of early stories surrounding the 
clinical launch of the drug in 1998, the majority of press coverage has 
occurred since 2003, with sport, as noted above, featuring prominently in 
2003, and a more even distribution of themes the following year 2004. 
Since then, however, medical and lifestyles themes seem to have 
 7
predominated, though our sample, to repeat, only takes us up to 31st of 
August 2006.  
 
It is to a more detailed account of each of these key themes that we now 
turn. 
 
(i) Medical conditions: from narcolepsy to…? 
 
The earliest reportage of Modafinil in our newspaper sample occurred in 
1998, when the drug was first launched in the UK. A story in The 
Independent (March 4th 1998), for example, entitled ‘Wonder wake-up 
boosts alertness’ (in the ‘News’ section of the paper), informs us that ‘A 
wake-up pill that increases alertness and boosts memory in people who 
are sleep deprived was launched yesterday’. The drug, it is noted, ‘could 
provide the pharmacological equivalent of the electric light bulb’ (our 
emphasis). The bulk of the story, however, rests content with mere 
reportage, with no comment or judgement passed, of the somewhat 
delimited claims and ambitions of the manufacturers of the drug. The 
medical director of Cephalon UK, Dr Colin Makland, for instance, is 
quoted as saying that there are ‘no plans’ to explore the drugs potential as 
an ‘alertness pill’. ‘All our activities’, Makland assures us, ‘have been in 
the area of narcolepsy. If we wanted to seek another indication for the 
drug we would have to go back and conduct other studies’. 
 
Much of the newspaper coverage of the medical use of Modafinil, as this 
suggests, has narcolepsy somewhere in the storyline. This however took a 
variety of forms, from straightforward matter-of-fact reportage about the 
efficacy of the drug in the treatment of narcolepsy (sometime written by 
doctors or sleep experts themselves, particularly in the more ‘serious’ 
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papers), to more glowing reports of how this new wonder drug transforms 
lives through personal stories and case studies drawn from sufferers of 
narcolepsy themselves. We see this, for example, very clearly in an article 
in the Times (27th July, 2004), in its ‘Features’ section, which opens as 
follows: 
 
As a teenager, Brendan Maguire had to be careful not to laugh. If he 
did, he could fall to the floor in a deep sleep. He spent most of his 
days in bed because he always felt sleepy.  
 
Maguire has narcolepsy and his life was transformed two years ago by 
a new drug, Provigil, that allows him to live an almost normal life. 
‘Now I can do a 12 hour shift at a call centre’, he says. 
 
The Independent (September 28th, 2000), in similar fashion, carried a 
story (in the ‘Features’ section of the paper) entitled ‘Health: The fast 
asleep club’. ‘For sufferers from narcolepsy’, the paper notes, ‘fighting 
weariness is a way of life. They live everyday as if the previous 48 hours 
have been sleepless’. Sufferers are then drawn into the storyline, such as  
Kerry James, (a college lecturer), who became so bad that she ‘frequently 
fell asleep during meetings, over meals and once even had to find an 
empty teaching room in which to take a nap on the floor’. Kerry, the 
reader is told, was eventually diagnosed with narcolepsy and since then 
she has been taking Provigil, which means she ‘can now go virtually 
through the day without needing to nap’.  
 
Gradually however, over time, these narcolepsy based storylines are 
joined if not eclipsed by newspaper coverage of other clinical or 
experimental applications of the drug, again largely uncritical in tone and 
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content, for conditions such as obstructive sleep apnoea (OSA), multiple 
sclerosis, ‘shift work sleep disorder’ (SWSD) and Attention 
Deficit/Hyperactivity Disorder (ADHD). The Times (August 15th 2005), 
for example, in an article by Dr. Thomas Stuttaford, informs readers that 
Modafinil is useful not simply for the treatment of narcolepsy but also for 
‘…treating the daytime sleepiness associated with obstructive sleep 
apnoea’. Readers are also told in this article that ‘The New England 
Journal of Medicine has recently reported on another use for Provigil: 10 
per cent of night-shift workers find that the irregular hours makes them 
excessive sleepy while they are working’. The ‘careful double-blind 
trial’, carried out by the Division of Sleep Medicine at Harvard 
University and researchers from other centres, Dr. Stuttaford informs the 
reader, ‘showed that Provigil did bring about modest improvement in the 
night-shift workers’ problems: they were more alert when working and 
their accident rate on the way home was significantly reduced’ (Times, 
15th August, 2005). 
 
Further justifications for these new clinical uses of Modafinil could also 
be discerned in other stories, particularly in terms of accident reduction or 
prevention. Dr. Hilary Jones, for example, in his ‘Drug of the Week’ 
column (Sunday Surgery, Health Section) in the News of the World (April 
11th, 2004), asks his readers: 
 
Do you nod off during the day? It’s a serious problem if you’re 
operating machinery or driving. 
 
Readers are then informed that: 
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Provigil (also known by its generic name Modafinil) boosts 
alertness and is prescribed in severe cases such as people with 
Parkinson’s disease. Many of Britain’s four million night workers 
could use it too (our emphases). 
 
Sleep experts and doctors are then drawn upon to provide further 
endorsement for these particular uses of the drug. The use of doctors and 
sleep experts indeed was a common theme in our newspaper sample. The 
Daily Mail, for example, quotes a consultant neurologist who stresses 
how this drug ‘really can transform people’s lives’, adding that it ‘should 
help people with a wide range of conditions where fatigue is an issue.The 
potential benefits are enormous’ (September 14th, 2004, our emphasis). 
 
As for the merits of Modafinil in relation to ADHD, another article in the 
Daily Mail a year later (20th December, 2005) -- this time with the 
attention grabbing headline ‘Anti-sleep drug can calm down little Barts’ -
- opens in the following fashion: 
 
Research shows that Provigil can have a dramatic effect on 
behaviour and attention span in children with Attention Deficit 
Hyperactivity Disorder (ADHD). 
 
The article, however, in a variant on the theme of medical expertise, 
concludes with a quote from a representative of the ADHD information 
service, Andrea Bilbow, who states that: ‘the “stay awake” pill had 
already been tested on adults with ADHD and seemed to work well…If it 
proves to have few side-effects, then it is obviously going to be a useful 
treatment.’ 3  
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Beyond this condition specific coverage, however, it was possible to 
discern other more amorphous, nebuluous, references made in the press to 
notions of  ‘excessive’ sleepiness or an ‘inability to stay awake’ as the 
clinical target or referent for this drug. The Daily Mail (September 14th, 
2004), for example, informs its readers that ‘doctors say Provigil (also 
known as Modafinil) – now licensed for use in the UK for the treatment 
of excessive sleepiness – is great news for patients plagued by the 
inability to stay awake’. Provigil, the reader is told, repeating the medical 
mantra, ‘can can change people’s lives. Patients who have been living in 
a fog of sleepiness for years find that in a few days the clock has been 
turned back and they’re able to live a normal life again’ (our emphases). 
 
There is then, as these extracts clearly show, precious little in this 
newspaper coverage that is critical or even cautious of this expanding list 
of clinical conditions for which Modafinil is currently prescribed or 
potentially applicable. The guiding template, instead, seems to be a 
matter-of-fact or upbeat style of reportage, about the clinical benefits of 
this drug, aided and abetted by personal testimonies, the latest findings 
from clinical trials and/or the views of this or that sleep expert. At most 
what one gets here in the way of critical coverage are occasional qualified 
comments such as ‘Provigil has revolutionised the treatment of 
narcolepsy but cannot be used indiscriminately. It may causes over-
excitement or irritability’ (Times, September 8th, 2003) or a lone, 
dissenting if not ‘maverick’ voice, cast in these very terms, such as John 
Mortimer, whose polemical piece in the Daily Mail, (November 14th, 
2002) is comically entitled: ‘A pill to help my memory? Forget it!’ 
Modafinil, he notes:  
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…a drug once used for sleeping sickness (sic), can – so Professor 
Robins of Cambridge University has discovered – sharpen short-
term memory and help problem-solving and planning. 
 
But forgetfulness, Mortimer protests, can be ‘a great excuse’ or ‘alibi’. 
‘How terrible it would be’, then, ‘if the usual excuse of forgetting met 
with: “Well take a large dose of Modafinil and come back when you’ve 
remembered”’. And  suppose, ‘in a moment of weakness, that we took the 
medicine?’, he continues: 
 
How painful, how unbearably overcrowded our minds would 
become…So let us keep the clouds of unknowing where we can 
hide the past, lit by only occasional shafts of memory. 
 
Whilst Mortimer provides something of a lone or dissenting voice as far 
as the clinical merits of Modafinil are concerned, he is nevertheless in 
good company when it comes to media concerns over the use of this drug 
for non-clinical reasons or non-medical purposes. 
 
 
(ii) Lifestyle choices: flexible workers and party people; 
 
Another key concern articulated and conveyed in this press coverage of 
Modafinil, pertains to the potential of the drug to blur the boundaries 
between the aforementioned ‘legitimate’ treatment of medical conditions  
and its uses and abuses as a (lifestyle) drug of choice.  
 
Again we see this articulated in the press in a variety of ways. The Daily 
Mail (January 5th 2004), for example, in a brief article on the drug, notes 
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how ‘critics fear this could lead to the use of Provigil being extended to 
healthy people who are simply short of sleep’. ‘Patients with demanding 
careers and lifestyles’, the reader is told, are ‘already beginning to ask for 
Provigil’. The Times, in a spate of articles in 2004 and 2005, articulate 
and amplify similar concerns. The Sunday Times (July 4th 2004), for 
instance, carried a story (in the ‘Home News’ section of the paper) 
proclaiming in the headline that ‘Downtime is over as pill offers 24-hour 
living’. ‘A pill that helps users feel wide awake after long periods without 
sleep’, it states, ‘is being tipped as the latest lifestyle “wonder drug” to 
hit Britain’ (our emphasis). The article then proceeds to use the situation 
in America to raise concerns in the UK: 
 
…the pill has been credited with fuelling the rise of the ‘24-hour 
society’ by helping truckers, students, night-clubbers and 
international travellers stay awake through the night or cope with 
jet lag. The drug has achieved sales of £250m a year. 
 
Now the same thing may happen here. The Medicines and 
Healthcare products Regulatory Agency has quietly decided to 
loosen the tight restrictions governing who can be prescribed 
Provigil. 
 
American users, the reader is told, ‘describe in enthusiastic terms how the 
pill has enabled them to stay awake without the jitteriness and anxiety 
brought about by large doses of caffeine’. As such, it is claimed, the drug 
could ‘undergo the “Viagra phenomenon”, in which its main use would 




Various expert viewpoints are then drawn into the picture, this time 
sounding a strong note of concern and caution about the potential uptake 
of this drug. Professor Martha Farah, for example, director of the centre 
for cognitive neuroscience at the University of Pennsylvania, is quoted as 
saying that Provigil had already accelerated America’s trend to becoming 
a 24-7 society and would do the same in Europe. ‘This drug enables us to 
be even more workaholic and obsessed with accomplishments and 
productivity’, she says, ‘It takes away the natural checks on that tendency 
– like needing to go to bed’ (Sunday Times, 4th July, 2004). 
 
This particular article is also notable for the way in which it draws the 
manufacturers of Modafinil, Cephalon Inc. into the picture. On the one 
hand, it is noted, how: ‘Cephalon, the company behind Provigil, says it is 
horrified at the lifestyle “abuse” of its drug’. On the other hand readers 
are informed that: 
 
Cephalon’s earlier marketing told a different story. Two years ago 
it was reprimanded by the Food and Drugs Administration -- 
America’s regulatory body – for the ‘dissemination of false or 
misleading promotional materials for Provigil’ (Sunday Times, 4th 
July, 2004). 
 
Two further stories in the Times underline these concerns. In the first,  
which appeared in the ‘Features’ section of the paper (July 27th, 2004), it 
is noted how, in the U.S., Provigil is ‘largely used for non-medical 
reasons – to sustain a party or business lifestyle without apparent 
penalties’. Provigil, the article continues: ‘…blurs the line between 
treating a medical condition and a lifestyle choice’ (our emphasis), 
noting moreover, through a direct quote from Professor Jim Horne, (of 
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the Sleep Research Centre at Loughborough University), that ‘we don’t 
know the long-term effects of using drugs to stay awake longer’. ‘What 
we do know’, Horne says, ‘is that there are powerful mechanisms for 
sleep and no natural ways to override them, so it’s a potentially 
dangerous thing to do’. 
 
The second article, a year later (July 2nd 2005), in the ‘Features: Body & 
Soul’ section of the newspaper, provides something of a curtain raiser for 
a Times sponsored event at the Science Museum’s Dana Centre entitled 
‘Night Creatures’. The key question this article poses if not answers is 
whether or not we ‘really want to stay up all night?’ Increasingly, the 
article notes, ‘especially in America, people are resorting to the new 
“stay-awake” drug Provigil, which promises six or seven hours of 
alertness with no problems falling asleep afterwards’. ‘But is this the right 
way to deal with the issue?’ the article asks: 
 
Drawing an analogy with food, are we indulging in a form of 
‘somorexia’, a deluded and unhealthy belief that we can do without 
sleep…Or is the whole notion that our 24/7 lifestyle is creating a 
nationwide sleep-debt itself a delusion? 
 
The problem however, the article concedes, in somewhat pessimistic 
tones, is that: 
 
…there is little chance of turning back the clock on our open-all-
night society. We have expanding demands on our time and 
increasing numbers of people do shift work. Hence the attraction of 
Provigil, a drug originally licensed to treat narcolepsy…Its sales 
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have rocketed in the past two years, from $300 million to $600 
million (£166 to £322 million). 
 
A further variant on this type of coverage concerned a more specific 
focus on Internet access to this drug. The Independent (April 18th, 2006), 
for example, in a Features section article entitled ‘My pills.co.uk’, ran a 
story alerting us to the fact that ‘some of the world’s best selling 
prescription drugs are not simply being taken by the sick but are also 
being used as “lifestyle medications”’ though the Internet. The ease of 
availability of virtually every kind of drug over the Internet, readers are 
told, has meant that ‘many people are now simply bypassing their doctor 
and self-prescribing medicines which they hope will improve their looks, 
job performance or prowess in the bedroom rather than treat a specific 
condition or disease’ (our emphases). There is even, the article warns, a 
‘darker side to the “lifestyle drugs” industry’, in which ‘many drugs sold 
online are fakes that at best will not have the effect and at worst could 
kill’. Provigil is then drawn into the picture, alongside other drugs such as 
Prozac, Ritalin, Viagra and the statin Lipitor, noting how strict 
regulations on prescribing Provigil were eased two years ago, and how 
‘clubbers are using it to keep partying through the night, while 
businessmen are buying it to help them through long days in the office, 
and students are taking it to keep revising’. Doctors, it adds, have 
‘warned that the drug can be psychologically addictive and can induce 
headaches and nausea’.  
 
Not all articles, however, appeared to share these concerns, or at the very 
least seemed happy to endorse more widespread usage of the drug beyond 
any immediate clinical concerns. An article in the Times (August 15th, 
2005), for example, entitled ‘The pill that’s a wake up call’ (again by a 
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medical doctor in the ‘Features’ section of the paper), proclaimed in 
unqualified fashion, that: 
 
Judges who fall asleep on the bench, Cabinet ministers who can’t 
keep awake at public functions, and MPs who nod off in front of 
the television cameras in the House of Commons would all present 
a more alert and intelligent face to the world, and the cameras, if 
they took a small dose of Provigil (Modafinil) before their 
appearance. 
 
But ‘most importantly’, the article goes on to state, echoing the 
aforementioned theme of accident reduction or prevention: 
 
…lives would be saved on the roads, especially motorways, if 
long-distance drivers, whether in giant trucks or Minis, not only 
had regular rests but took the occasional Provigil tablet when there 
was any danger of them dropping off. 
 
Modafinil then, as this press coverage suggests, is indeed construed and 
constructed as a somewhat ‘controversial’ drug, precisely because of its 
appeal to a wide range of potential users and abusers in the name of work 
or play, productivity or pleasure. There is, however, another potential 
market for the drug that looms large in this press coverage, one that takes 
us far beyond the realms of civil society. 
 
(iii) Military operations: sleep as a ‘commodity’ of war; 
 
Military uses or deployments of Provigil also featured in our newspaper 
sample, particularly in the more ‘serious’ papers. As with medical uses of 
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the drug, some of this coverage adopted a rather matter-of-fact style of 
reporting, often in the context of a broader discussion of the drug and its 
potential applications. An article in the Daily Mail (January 5th 2004), for 
example, informs its readers of a ‘study of military helicopter pilots’ 
which ‘showed that the drug helped them stay alert and remain capable of 
performing complex tasks for almost two days without sleep’, without 
passing any significant comment.  
 
Other stories, however, chose instead to frame Provigil in terms of 
broader coverage of the problems of sleep deprivation for the military and 
the various efforts, both actual and on the horizon, to combat it. The 
Guardian (29th July 2004), for example, in an article entitled ‘Wired 
awake: Soldiers in the field go for days without rest’, notes how dealing 
with sleep deprivation is a ‘perennial problem for the military’, before 
drawing upon various military experts in the field to comment on this 
problem. ‘While drugs to combat sleepiness have their risks’, Greg 
Belensky (from the Walter Reed Army Institute of Research in Silver 
Spring, Maryland) states, ‘so too does deploying troops who aren’t 
sufficiently rested’. Belensky’s team, the reader is told, has ‘studied the 
effects of caffeine, speed and Provigil…on troops kept awake for up to 85 
hours’. Readers are also informed of other cutting edge developments, 
such as research conducted by Ruth Benca at the University of 
Wisconsin, Madison, funded by the US Department of Defence, which 
hopes, through investigation of the ‘biological secrets’ that allow 
migrating birds to exist on little or no sleep, to develop ‘not simply 
stimulants that keep you awake, but drugs that go a long way to removing 
the need for sleep’ (our emphasis). Efforts are also underway at 
Belensky’s lab, the reader is told, to: 
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…turn sleep into a commodity of war, much like bullets and fuel. 
In the next few months, troops will go on exercises wearing 
wristwatches that carefully monitor how much sleep they get… 
The wristwatches will also give advice on what stimulants, if any, 
should be taken, depending on the mission ahead. “The idea is to 
turn sleep into an item of logistic supply”, says Belensky. “We 
want to treat it like fuel – how much do people have, how long will 
it last them, and when do we need to fill them up again”, he says 
(our emphases). 
 
In this way, then, a variety of scenarios are rehearsed which provide, in 
effect, speculations on the future of sleep not simply for the military but 
for us all as these developments catch hold or take off. 
 
Particular flashpoints could also be discerned in this coverage. Perhaps 
the most striking illustration of this occurred in a spate of further 
Guardian articles in July 2004, couched in something of an investigative 
style designed to shock the reader. A headline on the first page of the 
Guardian (July 29th), for example, read: ‘Provigil is a drug able to keep 
pilots and combat troops awake for days. Now The Guardian can reveal 
the MoD bought thousands of pills in advance of the Iraq war’. The MoD, 
the article reports: 
 
…admitted to buying more than 24,000 Provigil pills, which are 
licensed in Britain only to help people with rare sleeping disorders 
shrug off daytime sleepiness. Experts say the new drug could be 




 ‘Military interest in Provigil’, the reader is told, ‘is fuelled by a desire to 
find alternatives to existing stimulants used to keep troops awake’, noting 
how ‘The US military has stepped up research into Provigil since the 
1990s’. 
 
Continuing this line of investigative style journalism, another article in 
the paper the following day (30th July 2004), by the same reporter in the 
‘Home pages’ section, reveals that scientists at Qinteg, the MoD’s main 
research contractor, are ‘preparing to publish research into the potential 
military uses of Provigil’ with the results due to be discussed in detail in 
October at the European Sleep Research Society meeting in Prague. 
‘Yesterday’, the article continues, (presumably in response to the 
previous day’s story), ‘the MoD said that the armed forces were not 
issued or prescribed Provigil or any other stimulants for operation or 
training purposes, adding that military stocks of Provigil were used only 
to treat those with narcolepsy and other rare sleep disorders’. The article 
concludes, however, by noting how ‘military forces around the world 
have been investigating Provigil as a means of keeping fatigued troops 
sharp in combat, since the early 90s’, including recommendations by 
French military researchers on the use of Provigil for missions lasting 24 
hours without sleep. A short letter in the ‘Comment & Analysis’ section 
of the paper duly follows, bearing the contentious title ‘Letters: Generals 
claim adds insult to injury’. In it Vice Admiral Ian Jenkins (Surgeon 
General, Ministry of Defence), reiterates that: ‘The MoD does not use 
Provigil for performance-enhancing purposes’.  
 
What we see here, then, in this newspaper coverage of Modafinil and the 
military, are a range of both real and imagined future scenarios which 
enable the press once again to rehearse a series of developments and 
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debates, concerns and anxieties about the uses and abuses of this drug, 
both on and off the battlefield. This includes the ‘leaky’ or ‘hybrid’ 
matter of the soldier’s body itself, which is increasingly being reworked 
or reconfigured through a series of cyborg couplings or human-machine 
fusions (cf. Haraway 1990, Gray 1995), thereby turning sleep into a 
‘commodity of war’ -- see also Ben-Ari (2003) on this theme.  
 
 
(iv)  (Un)Fair competition? The race to get ahead; 
 
The fourth and final theme in our sample, widely reported upon across all 
newspapers, concerned the use of Modafinil in sport. Much of this 
coverage centred around the controversial case of the US 100 and 200 
metres sprinter Kelli White, whose use of Modafinil proved to be the first 
test-case of its kind for the International Association of Athletics 
Federation (IAAF). This indeed was the only story covered by all the 
newspapers in our sample. 
 
We see this unfolding drama, for example, very clearly in a spate of 
articles in the Times, in 2003, which report how White tested positive for 
Modafinil at the 2003 World Championships in Paris, and how 
controversy followed, not simply over the reason for White’s use of this 
drug (a self-proclaimed case of narcolepsy) but whether or not Modafinil 
was in fact, or should be, classified as a ‘banned substance’ for IAAF 
purposes. In one article, bearing the header ‘White’s second positive test 
serves only to muddy the waters’ (Times, November 13th, 2003, ‘Sport’ 
section), for instance, we are told that: 
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Within a fortnight of the World Championships, Robert Wagner, 
White’s agent, handed a 25-page statement to Lunquist [chairman 
of the IAAF medical commission] which argued that Modafinil 
could not be considered a banned substance. Later that month, 
Cephalon, the worldwide manufacturer of the drug, sent a 
submission to Dick Pound, chief executive of Wada [World Anti- 
Doping Authority]. Paul Blake, senior vice-president of Cephalon, 
argued that Modafinil was not a stimulant, but a ‘wake-promoter’ 
and could not be related to any stimulant on the list. ‘It is a separate 
pharmacological entity’, Blake said. 
 
A subsequent article in the Guardian (May 19th, 2005), however, cast in 
more confessional tones, reveals how White, in coming clean to the 
World Anti-Doping Agency (Wada) at a hearing in Montreal, 
experimented with a ‘cocktail of banned substances’: 
 
 ‘I was offered a lot of things and asked to test them to see if I 
responded better to certain products’, she said. ‘I was like a guinea 
pig. I tried a lot of stimulants and Modafinil suited me perfectly. 
The same for tetrahydrogestrinone (THG), which helped put on 
muscle very quickly’. 
 
As for White’s claim to be suffering from narcolepsy, this, the reader is 
informed, was simply a ‘cover story’: ‘“I never suffered from 
narcolepsy”, White said. “I never even knew the word existed until a few 
hours after the announcement of my positive test”’.  
 
Whilst White is singled out for sustained press attention here, coverage 
also extended to reports of other athletes implicated in this controversy. 
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The Sun, (January 1st 2004), for example, ran a story entitled ‘Track ace 
Kelli fails test No. 2’ in which it is reported that ‘Now the US Olympic 
Committee have revealed White is one of seven athletes who failed drugs 
tests last summer’. ‘All seven atheletes’, the Sun notes, ‘are challenging 
the results. If Modafinil use is proved, it results in disqualification at the 
event at which a positive test occurred – but no suspension’. 
 
Modafinil, then, may very well be regarded as the latest in a long list of 
drugs and substances banned for use in sport, raising once again the 
spectre of unfair advantage. It is nonetheless, as White’s particular story 
clearly attests, instructive on a number of further counts, not least in 
terms of: (i) bogus appeals to medical conditions as (il)legimate grounds 
for using this drug; (ii) the ensuing IAAF, WADA and USADA 
deliberations as to whether or not Modafinil was in fact a ‘banned 
substance’, and perhaps most importantly of all; (iii) the role of the 
pharmaceutical industry itself in this critical test case. In reporting on 
these issues, therefore, the press again provide an effective vehicle for the 
articulation of a broader series of moral concerns and agendas regarding 
the potential uses and abuses of this drug in the competition or race to get 
ahead. 
 
Discussion and concluding remarks 
 
This study has been primarily concerned with discourses and debates on 
Provigil/Modafinil in the British national press. Further work, as such, is 
clearly needed not simply in terms of the social construction of this drug 
in other types of media, both new and old, but in relation to questions of 
audience reception/response as well as the specific cultures and 
institutional arrangements involved in the production of newsworthy 
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stories in this domain. Our data nonetheless, returning to the questions 
posed at the beginning of this paper, are instructive on a number of counts 
and at a number of different levels.  
 
In terms of the content of newspaper coverage, constructions of 
Modafinil in the press, as we have seen, cluster around four key themes 
pertaining to the medical, lifestyle, military and sporting uses and abuses 
of the drug -- with greatest coverage accorded to the latter theme  (see 
Table 1), due to a particular scandal emerging in 2003 concerning the use 
of the drug (see Table 2). Whilst medical uses of Provigil, in this respect, 
are largely portrayed in unproblematic, uncritical terms – proclaiming it 
something of a ‘wonder drug’ for the treatment of a growing list of 
medical conditions -- other non-medical uses are a source of considerable 
press concern, if not outright condemnation, particularly as a lifestyle 
drug of choice or as performance enhancer. The concern here seems to be 
the manner in which Modafinil, like Viagra before it, serves to further 
blur the lines between treatment and enhancement (itself of course a 
socially constructed and contested division): the latest expression indeed 
of on-going social and ethical debates in relation to a variety of new 
medical technologies (Rose 2007, Miller and Wilsdon 2006, Brown and 
Webster 2004, Parens 1998). Military deployments of Modafinil also 
receive critical coverage, though tempered somewhat by an 
acknowledgement that sleep deprivation is a real problem in certain 
(sustained) military operations, and that whilst drugs to combat 
sleep(iness) have their risks, so too do sleepy soldiers in combat. To the 
extent, moreover, that reportage of these military deployments provide an 
opportunity for the press to rehearse a series of current concerns and 
future scenarios regarding the fate of sleep in ‘24/7 society’ (Moore Ede 
1993), then they serve to further draw the reader into the story line 
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turning sleep into a matter of public concern. The press, as such, are 
active constructors and arbitrators in these debates, thereby helping raise 
both the profile of this new drug and the problem of sleep(iness) in the 
public’s mind. 
 
So what then does this tell us about the relationship between medicine, 
the media and the pharmaceutical industry? Certainly the ‘textual link’ 
between people in society has never been more evident; everything these 
days, it seems, is mediated in one way or another by the media, though 
not all mediation is ‘textual’ of course. But does this, as Kroll-Smith 
(2003) implies in his musings on the social construction of sleepiness in 
the media, provide an opportunity to critique the more pedestrian or 
prosaic versions of the medicalisation thesis in terms of medicine’s 
attempts to capture public problems? Is what we are seeing here, in other 
words, a more or less clear-cut case of ‘Direct-to-Patient’ medicalisation 
on the part of the media, bypassing the doctor in the process? Well, yes 
and no. Certainly the news has become a key way, if not the key way, of 
mediating a pharmaceutical to the public, particularly in countries such as 
Britain where DTCA is not permitted. To the extent, furthermore, that 
what is conveyed is ‘news’, it is likely to be treated more seriously or 
credibly by readers than a full-page glossy add in a magazine for this or 
that Big Pharma product 4. To the extent, however, that journalists 
regularly draw on sleep experts and doctors of various sorts as sources of 
authority and expertise, and to the extent that the traditional doctor-
patient relationship is itself sometimes used as a media template or 
framing device for these stories (including calls for patients to visit their 
doctor if they are ‘excessively sleepy’ or suffering from particular sleep 
‘problems’ or ‘pathologies’), then the degree to which these media 
constructions can truly be regarded as ‘extra institutional’ forms of 
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‘rhetorical authority’ and/or bypassing the doctor is open to question. At 
most, it seems, the traditional doctor-patient relationship and the 
institutional authority of medicine is being ‘reworked’ or ‘reconfigured’ 
rather than replaced or bypassed altogether in and through this newspaper 
coverage. The media, in short, may play a variety of roles in relation to 
both doctors and drugs.  
 
This press coverage of Provigil also, however, alerts us to the limits of a 
solely or strictly medicalised interpretation of these issues, at least as far 
as the media are concerned. To the extent, indeed, that press concerns 
about the potential uptake of this drug cluster or centre around its actual 
or potential non-medical uses and abuses, then what we see here is the 
articulation or amplification of a series of cultural anxieties about the 
pharmaceuticalisation rather than the medicalisation of alertness, 
sleepiness and everyday/night life. Pharmaceuticalisation, in this sense, 
refers to the transformation of human conditions, capacities or 
capabilities into pharmaceutical matters of treatment or enhancement. As 
such it overlaps with but extends far beyond the realms of the medical or 
the medicalised and serves to further blur the boundaries between 
treatment and enhancement. In praising and/or criticising these 
developments, however, the media may (inadvertently) contribute to 
them, diffusing information and raising awareness of pharmaceutical 
products in the public’s mind, thereby facilitating their potential uptake in 
everyday/night life. Media coverage of pharmaceuticals, in short, may 
have paradoxical, or at the very least unintended, consequences. 
 
Here we arrive at the final question posed at the beginning of this paper 
as to what all this tells us about the (bio)politics of alertness and the 
governance of sleepy bodies in contemporary culture? Why precisely 
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would society want to regulate or govern sleepiness and alertness in this 
way? Who benefits? Again, of course, this is a question which takes us 
far beyond the relams of the medical or the medicalised to broader 
questions about the role of pharmaceuticals in society. One evocative or 
provocative answer to these questions comes in the shape of Agger’s 
(2004, 1989) musings on ‘Fast Capitalism’ 5. Capitalism, Agger argues, 
has appreciably speeded up since Marx’s time, and even since the post 
World War II period (see also Gleick (2000) and Virilio (1986) on this 
theme). The key words here are ‘acceleration’ and ‘instantaneity’. The 
rate of ‘communicating, writing, connecting, shopping, browsing, surfing, 
and working has increased’, Agger (2004: 3) proclaims, particularly since 
the advent of communication technologies and the Internet. Boundaries of 
all sorts, as a consequence, have become blurred or broken down. 
‘Nothing today’, it seems, is ‘off limits to the culture industries and other 
industries that colonize not only our waking hours but also our dreaming’ 
(2004: 3). The adjective fast, in this way, is intended to modify our sense 
of capitalism in two main ways: first, through the compression of time 
(cf. Harvey 1989 and Giddens 1991) as the ‘pace of everyday life 
quickens in order to meet certain economic imperatives and to achieve 
control’; second, through the ‘erosion of boundaries, which are effaced by 
a social order bent on denying people private space and time’ (Agger 
2004: 3-4, our emphasis).  
 
Nothing, to repeat, is off limit in the 24/7 era of fast capitalism. Sleep or 
sleepiness, as such, becomes a ‘problem’, or at least a potential problem, 
in need of a solution in an increasingly time-hungry, incessant culture: a 
quick fix technical solution, in the case of Modafinil, which amounts to a 
further colonization of the body and everyday/night life through 
pharmacological means. To the extent, moreover, that sleep represents an 
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attempt to ‘slow down’ (cf. Honoré 2004) or ‘opt out’ of society, albeit 
temporarily or periodically -- cf. Schwartz’s (1970) notion of sleep as a 
‘periodic remission’ from society -- then our ‘ways of escape’ are 
effectively closing down or diminishing in the 24/7 era of ‘fast’ 
capitalism where achievement is prized, alertness is emphasized and 
vigilance is valorised. Modafinil, indeed, is simply the first of a new 
wave of drugs, including CX717 currently in trial, that provide the 
pharmacological means to prolong, promote and police our wakefulness, 
fuelling claims (rightly or wrongly) that sooner or later we will be able to 
pharmacologically or genetically ‘switch’ or ‘turn sleep off’ altogether 
(Lawton 2006: 34).  
 
These issues in turn raise related questions of  ‘pharmacological 
Calvinism’  (Conrad 2007, Klerman 1972): the Puritan, disciplined, 
ascetic belief, that is to say, that we need to work hard in order to achieve 
a valued goal or objective rather than take drugs or medications as a 
short-cut to success. To the extent that drugs such as Modafinil embody 
the Protestant work ethic (cf. Weber 1930), or at the very least display an 
‘elective affinity’ to it, providing us with the pharmacological means to 
remain alert, sharpen concentration, boost cognition and work even 
harder at the things we value, then the very notion of pharmaceutical 
Calvinism takes on potentially troubling new dimensions 6. Expressed 
more broadly, what this amounts to perhaps is yet another prime 
expression or glimpse of our (future) ‘neurochemical selves’ (Rose 2003) 
and of the intimate or inextricable links now forged between what Rose 
(2007) has appositely termed ‘somatic ethics’ (ethics that accord a central 
place to corporeal, bodily existence) and the ‘spirit of biocapital’; 
developments that carry profound implications for who we are and who 
we want to be. 
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 In reporting on these developments and rehearsing these dilemmas, 
discourses and debates, the press, in effect, are not simply alerting us to 
the pharmacological fortunes of this new drug, but providing us with a 
potent preview or portent of what may one day, for better or worse, 
through biotechnological tampering or tinkering of various kinds, become 





1. These terms Modafinil and Provigil will be used interchangeably 
throughout the paper and reflect, in large part, their usage in the British 
newspaper sources surveyed. 
 
2. Dates of first loading for newspapers on the LN database were as 
follows: The Guardian 1984, The Times 1985, The Independent 1988, 
The Mail 1992, The Mirror 1995, The Sun 2000. 
 
3. Cephalon’s supplemental New Drug Application (sNDA) to market 
Modafinil (under the brand name Sparlon) for the treatment of ADHD in 
children and adolescents was finally rejected by the FDA in August 2006. 
 
4. Thanks to one of the anonymous referees for drawing this point to our 
attention. 
 
5. Thanks to one of the anonymous referees for highlighting this source. 
 
6. At the time of writing, the Times Higher Education Supplement has 
just published a full page feature on the use of Provigil and other so-
called ‘smart drugs’ in academia: a growing trend in the global academic 
community, it is suggested, in a time squeezed, performance pressured, 
results-driven culture such as ours (Tysome 2007; see also Bee 2007 and 
Martin 2007). This in turn suggests that press concerns over the uses and 
abuses of Modafinil in relation to wakefulness are now being joined by, if 
not eclipsed by, concerns over its cognitive/brain-boosting qualities as a 
‘smart drug’, particularly in educational contexts but also more widely in 
society at large.
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Times Guardian Independent Mirror Mail Sun (sub) 
Total 
Medical     7          3     6    1  17 
Lifestyle     5           2     2     9 
Military           4      1     5 
Competition    10      11        6     3    2    1   33 










‘98  ‘99 2000 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 (sub) 
Total 
Medical   2       1   2  6  4  2  17 
Lifestyle        4  3  2    9 
Military        5      5 
Competition         25  7  1    33 
(sub) Total   2       1  27 22  8  4   64 
 
 
* Figures in both Tables 1 & 2 exceed the total article count (54) given 
that two or more themes may appear in any one article. 
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